Advertisement

Medications Used for Diabetes Mellitus

  • Haya Abu GhazalehEmail author
  • Ehsan Khan
Chapter
  • 26 Downloads

Abstract

The focus of this chapter is the pathophysiology of the two predominant types of diabetes and their pharmacological management. The overall aim of treating diabetes is blood glucose management. This includes attempting to avoid high and low blood glucose levels occurring, thereby reducing the risk of complications. The management of diabetes is frequently demanding and multifactorial; understanding the pharmacological therapies available for the contemporary treatment of diabetes is a central aspect of a nurse’s knowledge and skill.

Keywords

Insulin Biguanides Sulphonylureas Glinides SGLT2 inhibitors Incretins 

References

  1. Barnea M, Haviv L, Gutman R, Chapnik N, Madar Z, Froy O (2012) Metformin affects the circadian clock and metabolic rhythms in a tissue-specific manner. Biochimi Biophys Acta 1822(11):1796–1806CrossRefGoogle Scholar
  2. Boxberger KH, Hagenbuch B, Lampe JN (2014) Common drugs inhibit human organic cation transporter 1 (OCT1)-mediated neurotransmitter uptake. Drug Metab Dispos 42(6):990–995PubMedPubMedCentralCrossRefGoogle Scholar
  3. Burcelin R (2010) The gut-brain axis: a major glucoregulatory player. Diabetes Metab 36(Suppl 3):S54–S58PubMedCrossRefGoogle Scholar
  4. Cernea S, Raz I (2011) Therapy in the early stage: incretins. Diabetes Care 34(Suppl 2):S264–S271PubMedPubMedCentralCrossRefGoogle Scholar
  5. de la Peña A, Yeo KP, Linnebjerg H, Catton E, Reddy S, Brown-Augsburger P, Morrow L, Ignaut DA (2015) Subcutaneous injection depth does not affect the pharmacokinetics or glucodynamics of insulin lispro in normal weight or healthy obese subjects. J Diabetes Sci Technol 9(4):824–830PubMedPubMedCentralCrossRefGoogle Scholar
  6. Diabetes UK (2017) Diabetes risk factors. https://www.diabetes.org.uk/Preventing-Type-2-diabetes/Diabetes-risk-factors/ Accessed 6 June 2017
  7. Diamant M, Blaak EE, De Vos WM (2011) Do nutrient–gut–microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? Obes Rev 12(4):272–281PubMedCrossRefGoogle Scholar
  8. Duerden M (2009) What are hazard ratios? http://www.bandolier.org.uk/painres/download/whatis/What_are_haz_ratios.pdf. Accessed 5 May 2019
  9. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1–based therapies. Gastroenterology 141(1):150–156PubMedPubMedCentralCrossRefGoogle Scholar
  10. Filippi CM, von Herrath MG (2008) Viral trigger for type 1 diabetes: pros and cons. Diabetes 57(11):2863–2871PubMedPubMedCentralCrossRefGoogle Scholar
  11. Fonseca VA (2009) Defining and characterizing the progression of type 2 diabetes. Diabetes Care 32(Suppl 2):S151–S156PubMedPubMedCentralCrossRefGoogle Scholar
  12. Forsmark CE (2016) Incretins, diabetes, pancreatitis and pancreatic cancer: what the GI specialist needs to know. Pancreatology 16(1):10–13PubMedCrossRefGoogle Scholar
  13. Frayling TM, Evans JC, Bulman MP, Pearson E, Allen L, Owen K, Bingham C, Hannemann M, Shepherd M, Ellard S, Hattersley AT (2001) Beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors. Diabetes 50(Suppl 1):S94PubMedCrossRefGoogle Scholar
  14. Gault VA (2018) RD Lawrence lecture incretins: the intelligent hormones in diabetes. Diabet Med 35(1):33–40PubMedCrossRefGoogle Scholar
  15. Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE (2012) Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 22(11):820PubMedPubMedCentralCrossRefGoogle Scholar
  16. Gupta V (2013) Glucagon-like peptide-1 analogues: an overview. Indian J Endocrinol Metab 17(3):413–421PubMedPubMedCentralCrossRefGoogle Scholar
  17. Hirsch LJ, Gibney MA, Albanese J, Qu S, Kassler-Taub K, Klaff LJ, Bailey TS (2010) Comparative glycemic control, safety and patient ratings for a new 4 mm× 32G insulin pen needle in adults with diabetes. Curr Med Res Opin 26(6):1531–1541PubMedCrossRefGoogle Scholar
  18. Hofman PL, Derraik JGB, Pinto TE, Tregurtha S, Faherty A, Peart JM, Drury PL, Robinson E, Tehranchi R, Donsmark M, Cutfield WS (2010) Defining the ideal injection techniques when using 5-mm needles in children and adults. Diabetes Care 33(9):1940–1944PubMedPubMedCentralCrossRefGoogle Scholar
  19. International Diabetes Federation (2017) IDF diabetes atlas, 8th edn. https://www.idf.org/e-library/epidemiology-research/diabetes-atlas.html. Accessed 12 Mar 2019
  20. International Hypoglycaemia Study group (2015) Minimizing hypoglycemia in diabetes. Diabetes Care 38(8):1583–1591CrossRefGoogle Scholar
  21. Iqbal A, Heller S (2016) Managing hypoglycaemia. Best Pract Res Clin Endocrinol Metab 30(3):413–430PubMedCrossRefGoogle Scholar
  22. Ji J, Lou Q (2014) Insulin pen injection technique survey in patients with type 2 diabetes in mainland China in 2010. Curr Med Res Opin 30(6):1087–1093PubMedCrossRefGoogle Scholar
  23. Kahn SE, Andrikopoulos S, Verchere CB (1999) Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48(2):241–253PubMedCrossRefGoogle Scholar
  24. Kahn SE, Cooper ME, Del Prato S (2014) Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383(9922):1068–1083PubMedCrossRefGoogle Scholar
  25. Kaneto H, Obata A, Shimoda M, Kimura T, Hirukawa H, Okauchi S, Matsuoka TA, Kaku K (2016) Promising diabetes therapy based on the molecular mechanism for glucose toxicity: usefulness of SGLT2 inhibitors as well as incretin-related drugs. Curr Med Chem 23(27):3044–3051PubMedCrossRefGoogle Scholar
  26. Karp I, Sivaswamy A, Booth C (2019) Does the use of incretin-based medications increase the risk of cancer in patients with type-2 diabetes mellitus? Pharmacoepidemiol Drug Saf 28(4):489–499.  https://doi.org/10.1002/pds.4746 CrossRefPubMedGoogle Scholar
  27. Kreugel G, Beijer HJM, Kerstens MN, Ter Maaten JC, Sluiter WJ, Boot BS (2007) Influence of needle size for subcutaneous insulin administration on metabolic control and patient acceptance. Eur Diabetes Nurs 4(2):51–55CrossRefGoogle Scholar
  28. Lee EY, Hwang S, Lee YH, Lee SH, Lee YM, Kang HP, Han E, Lee W, Lee BW, Kang ES, Cha BS (2017) Association between metformin use and risk of lactic acidosis or elevated lactate concentration in type 2 diabetes. Yonsei Med J 58(2):312–318PubMedPubMedCentralCrossRefGoogle Scholar
  29. Liang C, Bertoia ML, Ding Y, Clifford CR, Qiao Q, Gagne JJ, Dore DD (2018) Exenatide use and incidence of pancreatic and thyroid cancer: a retrospective cohort study. Diabetes Obes Metab 21(4):1037–1042CrossRefGoogle Scholar
  30. Lim GE, Brubaker PL (2006) Glucagon-like peptide 1 secretion by the L-cell. Diabetes 55(Suppl 2):S70–S77CrossRefGoogle Scholar
  31. Madsbad S (2016) Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 18(4):317–332PubMedCrossRefGoogle Scholar
  32. Medicines and Healthcare Products Regulatory Agency (2016). https://www.gov.uk/drug-safety-update/sglt2-inhibitors-updated-advice-on-the-risk-of-diabetic-ketoacidosis. Accessed 21 May 19
  33. Miller RE (1981) Pancreatic neuroendocrinology: peripheral neural mechanisms in the regulation of the islets of Langerhans. Endocr Rev 2(4):471–494PubMedCrossRefGoogle Scholar
  34. Miwa T, Itoh R, Kobayashi T, Tanabe T, Shikuma J, Takahashi T, Odawara M (2012) Comparison of the effects of a new 32-gauge× 4-mm pen needle and a 32-gauge× 6-mm pen needle on glycemic control, safety, and patient ratings in Japanese adults with diabetes. Diabetes Technol Ther 14(12):1084–1090PubMedCrossRefGoogle Scholar
  35. Mueckler M, Thorens B (2013) The SLC2 (GLUT) family of membrane transporters. Mol Asp Med 34(2–3):121–138CrossRefGoogle Scholar
  36. Nadkarni P, Chepurny OG, Holz GG (2014) Regulation of glucose homeostasis by GLP-1. In: Progress in molecular biology and translational science, vol 121, pp 23–65Google Scholar
  37. National Institute for Health and Care Excellence (2019) British national formulary. https://bnf.nice.org.uk/. Accessed 12 Mar 2019
  38. NHS Digital (2018) National diabetes audit 2017–2018: short report, characteristics of people with diabetes. https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/report-1-care-processes-and-treatment-targets-2017-18-short-report. Accessed 27 Feb 2019
  39. Pani LN, Nathan DM, Grant RW (2008) Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%. Diabetes Care 31(3):386–390PubMedCrossRefGoogle Scholar
  40. Robinson S, Kessling A (1992) Diabetes secondary to genetic disorders. Baillieres Clin Endocrinol Metab 6(4):867–898PubMedCrossRefGoogle Scholar
  41. Scheen AJ (2007) Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 46(2):93–108PubMedCrossRefGoogle Scholar
  42. Scheen AJ (2015) Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75(1):33–59CrossRefGoogle Scholar
  43. Tahrani AA, Barnett AH, Bailey CJ (2016) Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol 12(10):566–592PubMedCrossRefGoogle Scholar
  44. Thawabi M, Studyvin S (2015) Euglycemic diabetic ketoacidosis, a misleading presentation of diabetic ketoacidosis. North American journal of medical sciences, 7(6), 291PubMedPubMedCentralCrossRefGoogle Scholar
  45. Tushuizen ME, Bunck MC, Pouwels PJ, Bontemps S, Van Waesberghe JHT, Schindhelm RK, Mari A, Heine RJ, Diamant M (2007) Pancreatic fat content and beta-cell function in type 2 diabetic and non-diabetic males. Diabetes 30(11):2916–2921Google Scholar
  46. Van Dalem J, Brouwers MC, Stehouwer CD, Krings A, Leufkens HG, Driessen JH, de Vries F, Burden AM (2016) Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. Br Med J 13(354):i3625CrossRefGoogle Scholar
  47. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143(4):913–916CrossRefPubMedGoogle Scholar
  48. Weyer C, Tataranni PA, Bogardus C, Pratley RE (2001) Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 24(1):89–94PubMedCrossRefGoogle Scholar
  49. World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. WHO, Geneva. https://apps.who.int/iris/bitstream/handle/10665/66040/WHO_NCD_NCS_99.2.pdf?sequence=1&isAllowed=y. Accessed 12 Mar 2019Google Scholar
  50. Xu W, Mu Y, Zhao J, Zhu D, Ji Q, Zhou Z, Yao B, Mao A, Engel SS, Zhao B, Bi Y, Zeng L, Ran X, Lu J, Ji L, Yang W, Jia W, Weng J (2017) Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial. Sci China Life Sci 60(3):225–238PubMedCrossRefGoogle Scholar
  51. Yin J, Deng H, Qin S, Tang W, Zeng L, Zhou B (2014) Comparison of repaglinide and metformin versus metformin alone for type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 105(3):e10–e15PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King’s College LondonLondonUK

Personalised recommendations